Literature DB >> 10681383

Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

R W Wang1, D J Newton, N Liu, W M Atkins, A Y Lu.   

Abstract

Testosterone, terfenadine, midazolam, and nifedipine, four commonly used substrates for human cytochrome P-450 3A4 (CYP3A4), were studied in pairs in human liver microsomes and in microsomes from cells containing recombinant human CYP3A4 and P-450 reductase, to investigate in vitro substrate-substrate interaction with CYP3A4. The interaction patterns between compounds with CYP3A4 were found to be substrate-dependent. Mutual inhibition, partial inhibition, and activation were observed in the testosterone-terfenadine, testosterone-midazolam, or terfenadine-midazolam interactions. However, the most unusual result was the interaction between testosterone and nifedipine. Although nifedipine inhibited testosterone 6beta-hydroxylation in a concentration-dependent manner, testosterone did not inhibit nifedipine oxidation. Furthermore, the effect of testosterone and 7,8-benzoflavone on midazolam 1'-hydroxylation and 4-hydroxylation demonstrated different regiospecificities. These results may be explained by a model in which multiple substrates or ligands can bind concurrently to the active site of a single CYP3A4 molecule. However, the contribution of separate allosteric sites and conformational heterogeneity to the atypical kinetics of CYP3A4 can not be ruled out in this model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10681383

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

Review 1.  Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?

Authors:  Dmitri R Davydov; James R Halpert
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

2.  Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.

Authors:  Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

3.  Mixing apples and oranges: Analysis of heterotropic cooperativity in cytochrome P450 3A4.

Authors:  Daniel J Frank; Ilia G Denisov; Stephen G Sligar
Journal:  Arch Biochem Biophys       Date:  2009-06-26       Impact factor: 4.013

Review 4.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Correction to "Allosteric Interactions in Human Cytochrome P450 CYP3A4: The Role of Phenylalanine 213".

Authors:  Ilia G Denisov; Yelena V Grinkova; Prithviraj Nandigrami; Mrinal Shekhar; Emad Tajkhorshid; Stephen G Sligar
Journal:  Biochemistry       Date:  2019-06-06       Impact factor: 3.162

6.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

7.  Effect of borneol on cytochrome P450 3A enzyme and midazolam pharmacokinetics in rats.

Authors:  Rong Zhang; Sui-Qing Mi; Ning-Sheng Wang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-16       Impact factor: 2.441

8.  Effect of glutathione on homo- and heterotropic cooperativity in cytochrome P450 3A4.

Authors:  Dmitri R Davydov; Nadezhda Y Davydova; Tamara N Tsalkova; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2008-01-11       Impact factor: 4.013

9.  Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.

Authors:  Joel O Olubodun; Hermann R Ochs; Lisa L von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 10.  New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome.

Authors:  Narasimhulu Shakunthala
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.